Download PDF
Pharmacopsychiatry 2015; 48(03): 89-94
DOI: 10.1055/s-0034-1398506
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Lithium Use from 2000 to 2010 in Italy: A Population-Based Study

A. Parabiaghi
1   IRCCS Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy
,
A. Barbato
1   IRCCS Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy
,
P. Risso
1   IRCCS Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy
,
I. Fortino
2   Regional Health Ministry, Lombardy Region, Milan, Italy
,
A. Bortolotti
2   Regional Health Ministry, Lombardy Region, Milan, Italy
,
L. Merlino
2   Regional Health Ministry, Lombardy Region, Milan, Italy
,
B. D’Avanzo
1   IRCCS Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, Italy
› Author Affiliations
Further Information

Publication History

received 18 June 2014
revised 31 October 2014

accepted 08 December 2014

Publication Date:
02 February 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: Lithium is a highly specific and evidence-supported drug for the acute and maintenance treatment of bipolar disorder.

Methods: The purpose of this study was to calculate the prevalence and incidence of lithium use and to investigate the prescribing patterns of other mood-stabilizing agents in lithium users. We analyzed lithium utilization from 2000 to 2010 in a large area in Italy on the basis of dispensing data drawn from the regional administrative database. For each calendar year those who had at least one recorded dispensation of lithium were defined as lithium users. Those who received more than 4 dispensations per year were defined as lithium-treated.

Results: Rates of lithium utilization did not change during the observation period, but the amount of drug prescribed increased as a result of longer treatment and higher doses. The prevalence of use showed an initial increase of 8% (2000–2002), followed by a 13% decrease (2002–2006) and a subsequent rise of 11% (2006–2010). The prevalence of treatment grew by 38% during the whole observation period. The proportion of former lithium users who received other drugs or discontinued any treatment increased from 41% in 2002 to 52% in 2006, and then fell to 40% in 2010.

Conclusion: The initial decline (2002–2006) and the subsequent rise (2006–2010) of lithium use can be explained by a fall and rise of new prescriptions. This finding together with a similar but opposite change in prescriptions of the other mood-stabilizing agents suggests a temporary change in prescribing attitudes which was subsequently reconsidered.

Key words

bipolar disorder - lithium - drug utilization
 

  • References

  • 1 Baldessarini RJ, Leahy L, Arcona S et al. Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders. Psychiatr Serv 2007; 58: 85-91
    CrossrefPubMedGoogle Scholar
  • 2 Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-352
    PubMedGoogle Scholar
  • 3 Schou M, Juel-Nielsen N, Stromgren E et al. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 1954; 17: 250-260
    CrossrefPubMedGoogle Scholar
  • 4 Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-250
    CrossrefPubMedGoogle Scholar
  • 5 Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980; 2: 279-288
    CrossrefPubMedGoogle Scholar
  • 6 Cousins DA, Young AH. The armamentarium of treatments for bipolar disorder: a review of the literature. Int J Neuropsychopharmacol 2007; 10: 411-431
    CrossrefPubMedGoogle Scholar
  • 7 Schou M. Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 1998; 31: 210-215
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Malhi GS, Adams D, Berk M. Is lithium in a class of its own? A brief profile of its clinical use. Aust NZ J Psychiatry 2009; 43: 1093-1104
    PubMedGoogle Scholar
  • 9 McKnight RF, Adida M, Budge K et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-728
    CrossrefPubMedGoogle Scholar
  • 10 Geddes J, Miklowitz D. Treatment of bipolar disorders. Lancet 2013; 381: 1672-1682
    CrossrefPubMedGoogle Scholar
  • 11 Grunze H, Vieta E, Goodwin GM et al. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013; 14: 154-219
    CrossrefPubMedGoogle Scholar
  • 12 Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-940
    CrossrefPubMedGoogle Scholar
  • 13 Cipriani A, Hawton K, Stockton S et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346: f3646
    CrossrefPubMedGoogle Scholar
  • 14 Blanco C, Laje G, Olfson M et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002; 159: 1005-1010
    CrossrefPubMedGoogle Scholar
  • 15 Davids E, Bunk C, Specka M et al. Psychotropic drug prescription in a psychiatric university hospital in Germany. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1109-1116
    CrossrefPubMedGoogle Scholar
  • 16 Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use?. Br J Psychiatry 2007; 191: 474-476
    CrossrefPubMedGoogle Scholar
  • 17 Wilting I, Souverein PC, Nolen WA et al. Changes in outpatient lithium treatment in the Netherlands during 1996–2005. J Affect Disord 2008; 111: 94-99
    CrossrefPubMedGoogle Scholar
  • 18 Castells X, Vallano A, Rigau D et al. Trends in lithium prescription in Spain from 1985 to 2003. J Affect Disord 2006; 91: 273-276
    CrossrefPubMedGoogle Scholar
  • 19 Hayes J, Prah P, Nazareth I et al. Prescribing trends in bipolar disorder: Cohort study in the United Kingdom THIN Primary Care Database 1995–2009. PLoS ONE 2011; 6: e28725
    CrossrefPubMedGoogle Scholar
  • 20 Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust NZ J Psychiatry 2013; 47: 74-87
    CrossrefPubMedGoogle Scholar
  • 21 Bramness JG, Ringbäck Weitoft G, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affective Disord 2009; 118: 224-228
    CrossrefPubMedGoogle Scholar
  • 22 Franchi C, Tettamanti M, Pasina L et al. Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM – Elderly Project 2000–2010. Eur J Clin Pharmacol 2014; 70: 437-443
    CrossrefPubMedGoogle Scholar
  • 23 Percudani M, Barbui C, Fortino I et al. Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord 2004; 83: 169-175
    CrossrefPubMedGoogle Scholar
  • 24 WHO Collaborating Centre for Drug Statistics Methodology The Anatomical Therapeutic Chemical (ATC) classification. About the ATC/DDD system. Available at: http://www.whocc.no/atcddd - accessed December 1, 2013
    PubMed
  • 25 Panconesi A, Pavone E, Vacca F et al. Triptans in the Italian population: a drug utilization study and a literature review. J Headache Pain 2008; 9: 71-76
    CrossrefPubMedGoogle Scholar
  • 26 Ferrari AJ, Baxter AJ, Whiteford HA. A systematic review of the global distribution and availability of prevalence data for bipolar disorder. J Affect Disord 2011; 134: 1-13
    CrossrefPubMedGoogle Scholar
  • 27 Vallarino M, Rapisarda F, Parabiaghi A et al. Do patients with bipolar disorders receive evidence-based psychosocial interventions? a survey in Italy. Eur Psychiat 2011; 26 (S1) 25
    CrossrefPubMedGoogle Scholar
  • 28 Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-940
    CrossrefPubMedGoogle Scholar
  • 29 Baldessarini RJ, Tondo L, Davis P et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-639
    Google Scholar